Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Maurer, MS; Elliott, P; Merlini, G; Shah, SJ; Cruz, MW; Flynn, A; Gundapaneni, B; Maurer, MS; Elliott, P; Merlini, G; Shah, SJ; Cruz, MW; Flynn, A; Gundapaneni, B; Hahn, C; Riley, S; Schwartz, J; Sultan, MB; Rapezzi, C; ATTR-ACT Study Investigators, ; - view fewer (2017) Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circulation: Heart Failure , 10 (6) 10.1161/CIRCHEARTFAILURE.116.003815 .

http://ift.tt/2uIKQTK